Beta adrenergic receptor: Difference between revisions

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
m (create)
(add content based on adrenergic receptor page)
Line 1: Line 1:
{{Disambiguation}}
The '''adrenergic receptors''' (or adrenoceptors) are a class of guanine nucleotide regulatory binding protein receptors (G protein-coupled receptors) that are targets of the [[catecholamine]]s, especially [[norepinephrine]] (noradrenaline) and [[epinephrine]] (adrenaline).<ref name="Wachter2012">{{Cite journal|last=Wachter|first=S. Blake|last2=Gilbert|first2=Edward M.|date=2012|title=Beta-Adrenergic Receptors, from Their Discovery and Characterization through Their Manipulation to Beneficial Clinical Application|url=https://www.karger.com/Article/FullText/339271|journal=Cardiology|language=en|volume=122|issue=2|pages=104–112|doi=10.1159/000339271|issn=0008-6312|pmid=22759389}}</ref><br>
Did you mean:
 
* [[adrenergic receptor]]  
'''Adrenergic receptors''' mediate the effects of norepinephrine, epinephrine, and many adrenergic prescription drugs.<ref name="Bylund2013">{{Cite book|last=Bylund|first=D. B.|date=2013-01-01|editor-last=Lennarz|editor-first=William J.|editor2-last=Lane|editor2-first=M. Daniel|title=Adrenergic Receptors|url=http://www.sciencedirect.com/science/article/pii/B9780123786302003340|language=en|location=Waltham|publisher=Academic Press|pages=57–60|isbn=978-0-12-378631-9}}</ref>
 
<!--
=== Alpha adrenergic receptors ===
Alpha adrenergic receptors or adrenergic receptors, also known as α-ARs or α-AdRs.
 
The alpha adrenergic receptors are:
* α1-adrenergic receptors (α1-AR)
* [[α2-adrenergic receptor]]s (α2-AR)<ref name="Wachter2012"/>
-->
==Types==
Beta adrenergic or β adrenergic receptors are also known as β-ARs or β AdR, have a key role in cardiac  regulation.<ref name="Wachter2012"/> 
 
The beta-adrenergic receptors are:
* β1-adrenergic receptors (β1-AdR)
* [[Beta 2-adrenergic receptor|β2-adrenergic receptors]] (β2-AdR)
* β3-adrenergic receptors (β3-AdR)<ref name="Wachter2012" />
 
== ME/CFS ==
In 2015, a relatively large German study found 29% of [[ME/CFS]] patients had elevated autoantibodies to M3 and M4 [[muscarinic acetylcholine receptor]]s, as well as ß2 adrenergic receptors.<ref name="Loebel2016" />
 
In 2020, a small Sweden study confirmed these results in two different patient cohorts, but did not find a relationship between adrenergic receptors and the severity of ME.<ref name="Bynke2020" /> The study assessed patients with moderate ME who met the [[Canadian Consensus Criteria|Canadian]] and [[International Consensus Criteria|international consensus criteria]] for [[Myalgic encephalomyelitis|ME]], plus the [[Systemic Exertion Intolerance Disease]] criteria, and found that the majority of patients had raised blood plasma concentration of β1, β2, M3 and M4-receptor autoantibodies but cerebral spinal fluid levels were normal. Only 25% of healthy controls had raised autoantibody levels.<ref name="Bynke2020" /> These findings supported the [[autoimmune hypothesis]] for a subset of patients.
 
== Notable studies ==
*2012, Differences in metabolite-detecting, adrenergic, and immune gene expression after moderate exercise in patients with chronic fatigue syndrome, patients with [[multiple sclerosis]], and healthy controls<ref name="White, 2012">{{Cite journal
| last1  = White                  | first1 = AT                  | authorlink1 =
| last2  = Light                  | first2 = AR                  | authorlink2 = Alan Light
| last3  = Hughen                | first3 = RW                  | authorlink3 =
| last4  = Vanhaitsma            | first4 = TA                  | authorlink4 =
| last5  = Light                  | first5 = KC                  | authorlink5 = Kathleen Light
| title  = Differences in metabolite-detecting, adrenergic, and immune gene expression after moderate exercise in patients with chronic fatigue syndrome, patients with multiple sclerosis, and healthy controls
| journal = Psychosomatic Medicine    | volume = 74  | issue = 1  | page = 46-54| date    = 2012| pmid    = | pmc = PMC3256093 | url = https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256093/
| doi    = 10.1097/PSY.0b013e31824152ed}}</ref> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256093/ (Full text)]
*2016, Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome
<ref name="Loebel2016 ">{{Cite journal|last1  = Loebel            | first1 = M          | authorlink1 = Madlen Loebel | last2  = Grabowski        | first2 = P          | authorlink2 = Patricia Grabowski| last3  = Heidecke          | first3 = H        | authorlink3 = | last4  = Bauer            | first4 = S          | authorlink4 = | last5  = Hanitsch          | first5 = LG          | authorlink5 = | last6  = Wittke            | first6 = K          | authorlink6 = | last7  = Meisel            | first7 = C          | authorlink7 = | last8  = Reinke            | first8 = P          | authorlink8 = | last9  = Volk              | first9 = H          | authorlink9 = | last10  = Fluge            | first10 = Ø          | authorlink10 = Øystein Fluge| last11  = Mella            | first11 = O        | authorlink11 = Olav Mella| last12  = Scheibenbogen    | first12 = C          | authorlink12 = Carmen Scheibenbogen| title  = Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome| journal = Brain, behavior, and immunity    | volume = 52  | issue =    | page = 32-39| date    = 2016 | doi    = 10.1016/j.bbi.2015.09.013 | url = https://www.sciencedirect.com/science/article/pii/S0889159115300209
}}</ref> -[https://www.sciencedirect.com/science/article/pii/S0889159115300209?via%3Dihub (Full Text)]
*2018, [[Immunoadsorption]] to remove ß2 adrenergic receptor antibodies in [[Chronic Fatigue Syndrome]] [[ME/CFS|CFS/ME]]<ref name="Immunoadsorption2018">{{Cite journal|last=Scheibenbogen|first=Carmen|author-link=Carmen Scheibenbogen|last2=Loebel|first2=Madlen|author-link2=Madlen Löbel|last3=Freitag|first3=Helma|author-link3=Helma Freitag|last4=Krueger|first4=Anne|last5=Bauer|first5=Sandra|author-link5=Sandra Bauer|last6=Antelmann|first6=Michaela|last7=Doehner|first7=Wolfram|last8=Scherbakov|first8=Nadja|last9=Heidecke|first9=Harald|last10=Reinke|first10=Petra|last11=Volk|first11=Hans-Dieter|last12=Grabowski|first12=Patricia|author-link12=Patricia Grabowski|date=2018|title=Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME|url=http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0193672|journal=PLoS ONE|volume=13|issue=3|pages=e0193672|doi=10.1371/journal.pone.0193672|via=}}</ref> - [http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0193672 (Full Text)]
* 2020, Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients – A validation study in plasma and cerebrospinal fluid from two Swedish cohorts<ref name="Bynke2020">{{Cite journal|last=Bynke|first=Annie|author-link=|last2=Julin|first2=Per|author-link2=|last3=Gottfries|first3=Carl-Gerhard|author-link3=Carl-Gerhard Gottfries|last4=Heidecke|first4=Harald|author-link4=|last5=Scheibenbogen|first5=Carmen|author-link5=Carmen Scheibenbogen|last6=Bergquist|first6=Jonas|author-link6=Jonas Bergquist|date=2020-08-01|title=Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients – A validation study in plasma and cerebrospinal fluid from two Swedish cohorts|url=http://www.sciencedirect.com/science/article/pii/S2666354620300727|journal=Brain, Behavior, & Immunity - Health|language=en|volume=7|issue=|pages=100107|doi=10.1016/j.bbih.2020.100107|issn=2666-3546|pmc=|pmid=|access-date=|quote=|via=}}</ref> - [http://www.sciencedirect.com/science/article/pii/S2666354620300727 (Full text)]
 
*2020, Comparison of Beta-2 Adrenergic Receptor Gene Polymorphisms Between Patients with Fibromyalgia Syndrome and Healthy Controls<ref name="Cakiroglu2020">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788641/</ref> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788641/ (Full text)]
* 2021,
 
==News articles and blogs==
* 2015, [https://www.meaction.net/2015/09/26/antibodies-found-in-subset-of-cfs-patients/ Autoantibodies found in subset of CFS patients] - #MEAction
 
== Learn more ==
* [https://doi.org/10.1159/000339271 Beta-Adrenergic Receptors, from Their Discovery and Characterization through Their Manipulation to Beneficial Clinical Application]
 
==See also==
* [[beta 2-adrenergic receptor]]
* [[beta 2-adrenergic receptor]]
* [[Wirth-Scheibenbogen hypothesis]]
*[[Autoimmune hypothesis]]
*[[Muscarinic acetylcholine receptor]]
*[[Neurotransmitters]]
==References==
{{Reflist}}


[[Category:Protein receptors]]
[[Category:Protein receptors]]
[[Category:Biochemistry and cell biology]]
[[Category:Biochemistry and cell biology]]

Revision as of 21:18, January 18, 2022

The adrenergic receptors (or adrenoceptors) are a class of guanine nucleotide regulatory binding protein receptors (G protein-coupled receptors) that are targets of the catecholamines, especially norepinephrine (noradrenaline) and epinephrine (adrenaline).[1]

Adrenergic receptors mediate the effects of norepinephrine, epinephrine, and many adrenergic prescription drugs.[2]

Types[edit | edit source]

Beta adrenergic or β adrenergic receptors are also known as β-ARs or β AdR, have a key role in cardiac regulation.[1]

The beta-adrenergic receptors are:

ME/CFS[edit | edit source]

In 2015, a relatively large German study found 29% of ME/CFS patients had elevated autoantibodies to M3 and M4 muscarinic acetylcholine receptors, as well as ß2 adrenergic receptors.[3]

In 2020, a small Sweden study confirmed these results in two different patient cohorts, but did not find a relationship between adrenergic receptors and the severity of ME.[4] The study assessed patients with moderate ME who met the Canadian and international consensus criteria for ME, plus the Systemic Exertion Intolerance Disease criteria, and found that the majority of patients had raised blood plasma concentration of β1, β2, M3 and M4-receptor autoantibodies but cerebral spinal fluid levels were normal. Only 25% of healthy controls had raised autoantibody levels.[4] These findings supported the autoimmune hypothesis for a subset of patients.

Notable studies[edit | edit source]

  • 2012, Differences in metabolite-detecting, adrenergic, and immune gene expression after moderate exercise in patients with chronic fatigue syndrome, patients with multiple sclerosis, and healthy controls[5] (Full text)
  • 2016, Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome

[3] -(Full Text)

  • 2020, Comparison of Beta-2 Adrenergic Receptor Gene Polymorphisms Between Patients with Fibromyalgia Syndrome and Healthy Controls[7] - (Full text)
  • 2021,

News articles and blogs[edit | edit source]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. 1.0 1.1 1.2 Wachter, S. Blake; Gilbert, Edward M. (2012). "Beta-Adrenergic Receptors, from Their Discovery and Characterization through Their Manipulation to Beneficial Clinical Application". Cardiology. 122 (2): 104–112. doi:10.1159/000339271. ISSN 0008-6312. PMID 22759389.
  2. Bylund, D. B. (January 1, 2013). Lennarz, William J.; Lane, M. Daniel (eds.). Adrenergic Receptors. Waltham: Academic Press. pp. 57–60. ISBN 978-0-12-378631-9.
  3. 3.0 3.1 Loebel, M; Grabowski, P; Heidecke, H; Bauer, S; Hanitsch, LG; Wittke, K; Meisel, C; Reinke, P; Volk, H; Fluge, Ø; Mella, O; Scheibenbogen, C (2016). "Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome". Brain, behavior, and immunity. 52: 32-39. doi:10.1016/j.bbi.2015.09.013.
  4. 4.0 4.1 4.2 Bynke, Annie; Julin, Per; Gottfries, Carl-Gerhard; Heidecke, Harald; Scheibenbogen, Carmen; Bergquist, Jonas (August 1, 2020). "Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients – A validation study in plasma and cerebrospinal fluid from two Swedish cohorts". Brain, Behavior, & Immunity - Health. 7: 100107. doi:10.1016/j.bbih.2020.100107. ISSN 2666-3546.
  5. White, AT; Light, AR; Hughen, RW; Vanhaitsma, TA; Light, KC (2012). "Differences in metabolite-detecting, adrenergic, and immune gene expression after moderate exercise in patients with chronic fatigue syndrome, patients with multiple sclerosis, and healthy controls". Psychosomatic Medicine. 74 (1): 46-54. doi:10.1097/PSY.0b013e31824152ed. PMC 3256093.
  6. Scheibenbogen, Carmen; Loebel, Madlen; Freitag, Helma; Krueger, Anne; Bauer, Sandra; Antelmann, Michaela; Doehner, Wolfram; Scherbakov, Nadja; Heidecke, Harald; Reinke, Petra; Volk, Hans-Dieter; Grabowski, Patricia (2018). "Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME". PLoS ONE. 13 (3): e0193672. doi:10.1371/journal.pone.0193672.
  7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788641/